The FDA approved elbasvir and grazoprevir (Zepatier, Merck) for the treatment of adults with chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection, with or without ribavirin (RBV). At a list price of $54,600 for a 12-week regimen, Zepatier will be priced lower than other direct-acting antiviral regimens. Merck said this price, as well as their comprehensive access strategy to seek broad coverage across commercial and public segments, will help broaden and
JANUARY 29, 2016